Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning

Ferdinándy, Péter; Hausenloy, Derek J.; Heusch, Gerd; Baxter, Gary F.; Schulz, Rainer

doi:10.1124/pr.113.008300

Cited by 506 publications

(512 citation statements)

References 403 publications

(375 reference statements)

Supporting

Mentioning

491

Contrasting

Unclassified

Order By: Relevance

“…17 Coexisting conditions (e.g., diabetes) and concomitant treatments (e.g., antiplatelet therapy) may also influence reperfusion injury and the response to protective interventions. 18 In the CIRCUS trial, however, we found no significant difference in these baseline characteristics (apart from smoking) between the two groups. 19,20 Hence, the lack of an effect with cyclosporine is unlikely to be related to the influence of any of these effect modifiers or coexisting conditions.…”

Section: Discussionmentioning

confidence: 52%

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

et al. 2015

View full text Add to dashboard Cite

BACKGROUNDExperimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODSIn a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTSA total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval, 0.78 to 1.39; P = 0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONSIn patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. ( n engl j med 373;11 nejm.org September 10, 2015 1022T h e ne w e ngl a nd jou r na l o f m e dicine O ver the past three decades, major progress has been made in the treatment of patients with ST-segment elevation myocardial infarction (STEMI).1 Nevertheless, the rates of death, heart failure, and recurrent ischemic events occurring in the first year after infarction remain unacceptably elevated in this highrisk population. Although many advances have been made in the development of methods to reopen the culprit coronary artery and prevent reocclusion, there is currently no specific treatment that targets myocardial reperfusion injury, which is a paradoxical form of myocardial damage that occurs as a result of the restoration of vessel patency.2 Growing evidence from experimental studies and small-size proof-of-concept clinical trials shows that reperfusion injury contributes greatly to the final infarct size.3-5 Preclinical studies indicate that the opening of the mitochondrial permeability transition pore (PTP) in the inner mitochondrial membrane plays a major role in reperfusion injury. ...

show abstract

Section: Discussionmentioning

confidence: 52%

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

et al. 2015

View full text Add to dashboard Cite

show abstract

“…175 Aging per se attenuates cardioprotective signaling, [176][177][178] although in 2 retrospective analyses for confounders, protection by remote ischemic preconditioning was seen in all age cohorts of patients undergoing surgical coronary revascularization 179 and protection by remote ischemic perconditioning was seen n.s. P P P P P P P P P P P P P P P P P in all age cohorts of patients with acute STEMI undergoing primary PCI.…”

Section: Lack Of Comorbidities and Comedications In Animal Experimentsmentioning

confidence: 99%

Time to Give Up on Cardioprotection?

2016

Self Cite

View full text Add to dashboard Cite

Abstract:The mortality from acute myocardial infarction (AMI) remains significant, and the prevalence of postmyocardial infarction heart failure is increasing. Therefore, cardioprotection beyond timely reperfusion is needed. Conditioning procedures are the most powerful cardioprotective interventions in animal experiments. However, ischemic preconditioning cannot be used to reduce infarct size in patients with AMI because its occurrence is not predictable; several studies in patients undergoing surgical coronary revascularization report reduced release of creatine kinase and troponin. Ischemic postconditioning reduces infarct size in most, but not all, studies in patients undergoing interventional reperfusion of AMI, but may require direct stenting and exclusion of patients with >6 hours of symptom onset to protect. Remote ischemic conditioning reduces infarct size in patients undergoing interventional reperfusion of AMI, elective percutaneous or surgical coronary revascularization, and other cardiovascular surgery in many, but not in all, studies. Adequate dose-finding phase II studies do not exist. There are only 2 phase III trials, both on remote ischemic conditioning in patients undergoing cardiovascular surgery, both with neutral results in terms of infarct size and clinical outcome, but also both with major problems in trial design. We discuss the difficulties in translation of cardioprotection from animal experiments and proof-ofconcept trials to clinical practice. Given that most studies on ischemic postconditioning and all studies on remote ischemic preconditioning in patients with AMI reported reduced infarct size, it would be premature to give up on cardioprotection. (Circ Res. 2016;119:676-695.

show abstract

“…These limitations contribute to the difficulties in translating data from animal studies to the patient with acute myocardial infarction undergoing reperfusion therapy, 8 apart from and in addition to confounding comorbidities and comedications. 190 …”

Section: Coronary Vascular Protection By Drugs and Cardioprotective Imentioning

confidence: 99%

The Coronary Circulation as a Target of Cardioprotection

2016

Self Cite

View full text Add to dashboard Cite

Abstract:The atherosclerotic coronary vasculature is not only the culprit but also a victim of myocardial ischemia/ reperfusion injury. Manifestations of such injury are increased vascular permeability and edema, endothelial dysfunction and impaired vasomotion, microembolization of atherothrombotic debris, stasis with intravascular cell aggregates, and finally, in its most severe form, capillary destruction with hemorrhage. In animal experiments, local and remote ischemic pre-and postconditioning not only reduce infarct size but also these manifestations of coronary vascular injury, as do drugs which recruit signal transduction steps of conditioning. Clinically, no-reflow is frequently seen after interventional reperfusion, and it carries an adverse prognosis. The translation of cardioprotective interventions to clinical practice has been difficult to date. Only 4 drugs (brain natriuretic peptide, exenatide, metoprolol, and esmolol) stand unchallenged to date in reducing infarct size in patients with reperfused acute myocardial infarction; unfortunately, for these drugs, no information on their impact on the ischemic/reperfused coronary circulation is available. (Circ Res.

show abstract

Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning

Cited by 506 publications

References 403 publications

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

Time to Give Up on Cardioprotection?

The Coronary Circulation as a Target of Cardioprotection

Contact Info

Product

Resources

About